Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × elotuzumab × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 15 Other hematologic neoplasm 1 Lymphoid 1

Conditions

Multiple Myeloma 1 Lymphoma 1

Interventions

Rituximab 468 Cyclophosphamide 369 Vincristine 190 Doxorubicin 166 fludarabine phosphate 148 Prednisone 146 Etoposide 146 fludarabine 141 Cytarabine 136 Methotrexate 133 Dexamethasone 109 Filgrastim 108 Lenalidomide 106 Granulocyte Colony-Stimulating Factor 98 Whole-Body Irradiation 92 ibrutinib 84 Mycophenolic Acid 81 Melphalan 74 Bendamustine Hydrochloride 74 Calcium Dobesilate 73 Bortezomib 70 Busulfan 67 Tacrolimus 66 Peripheral Blood Stem Cell Transplantation 64 obinutuzumab 57 ofatumumab 53 Radiotherapy 52 Cyclosporine 48 Antilymphocyte Serum 48 Alemtuzumab 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡